^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Testicular Seminoma

Related cancers:
26d
Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors. (PubMed, Cancer Res Commun)
These findings demonstrate a distinct surface antigen landscape in testicular GCTs, with CLDN6, EGFR, and TROP2 emerging as leading candidates for further translational evaluation. Enrichment of these targets highlights antigenic heterogeneity within GCTs and supports further validation in appropriate disease settings including metastatic, post-treatment, and relapsed or refractory disease.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • FOLR1 ( Folate receptor alpha ) • DLL3 (Delta Like Canonical Notch Ligand 3) • CLDN6 (Claudin 6) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • GPNMB (Glycoprotein Nmb) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
EGFR expression
27d
MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment. (PubMed, Front Immunol)
Testicular germ cell tumors (TGCTs) are the most common solid malignancies in young men and, despite high cure rates with cisplatin-based multimodal therapy, a clinically relevant subset of patients develops relapsed, platinum-refractory, or treatment-resistant disease with limited salvage options and substantial long-term morbidity...We argue that the next phase of the field should move beyond descriptive biomarker studies toward mechanism-based, TGCT-specific translational strategies integrating miRNA mimics, antagomirs, extracellular vesicles, or miRNA-augmented cellular therapies with immune-priming approaches such as epigenetic therapy, radiotherapy, vaccines, or CAR-T platforms. Such a framework could enable more precise biological stratification and improve the efficacy, durability, and tolerability of immunotherapy in refractory TGCT.
Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression • TMB-L
|
cisplatin
1m
A Rare Case of Seminoma in an Elderly Patient With Suspected Lynch Syndrome. (PubMed, Clin Case Rep)
These findings raise suspicion for Lynch syndrome. This case is interesting because seminoma and colorectal cancer were both identified in a patient with features suggestive of a hereditary cancer syndrome.
Journal
|
MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
1m
Differential diagnosis of testicular embryonal rhabdomyosarcoma and testicular seminoma with enhanced CT: a retrospective study. (PubMed, Front Oncol)
The median time to progression was 7 months (range 2-16.5 months). The existence of a parallel relationship between the lesion and the ipsilateral inguinal region, as well as the vascular ball sign, is helpful in differentiating testicular ERMS from testicular seminoma.
Retrospective data • Journal
|
AFP (Alpha-fetoprotein)
1m
Giant seminoma of the testis (2.51 kg) in a setting of severe occupational and lifestyle exposures: a case report and pathophysiological insights. (PubMed, Front Med (Lausanne))
Delayed diagnosis due to occupational neglect allowed the tumor to reach an exceptional size. Although causal associations remain to be established, preventive strategies that reduce exposure to environmental carcinogens, address occupational stress, ensure adequate sleep, and promote routine scrotal self-examination and timely medical consultation may be considered on general health grounds.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • ALPP (Alkaline Phosphatase, Placental) • SALL4 (Spalt Like Transcription Factor 4)
1m
HAVCR2 (TIM-3) as a favorable prognostic immune marker in seminoma: Integrative checkpoint screening and tissue validation. (PubMed, Cancer Treat Res Commun)
HAVCR2/TIM-3 expression demonstrates a consistent association with favorable clinical outcomes in seminoma across transcriptomic and protein-level analyses, with a lower risk of progression (HR = 0.201) in the pooled cohort. These exploratory findings support a potential prognostic role of TIM-3 reflecting an immune-active rather than exhausted microenvironment in seminoma, warranting prospective validation.
Journal • PD(L)-1 Biomarker • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
2ms
Very late extragonadal recurrence of testicular seminoma presenting as a bladder mass: a case report. (PubMed, Ann Med Surg (Lond))
It also emphasizes that normal tumor marker levels do not exclude recurrence and that histopathological confirmation remains essential for accurate diagnosis. Recognition of unusual presentations in long-term survivors of germ cell tumors is important to facilitate timely diagnosis and appropriate management.
Journal
|
AFP (Alpha-fetoprotein)
2ms
The RNA helicase DDX53 (CAGE) contributes to RNA metabolism in a human germ cell model. (PubMed, bioRxiv)
Our data indicate that DDX53 protein acts as a regulator of RNA metabolism in human cells. Collectively, we show that DDX53 participates in transcriptome regulation (including splicing) in male germ cells and exhibits transcriptomewide RNA interactions, but its wider biological role remains to be clarified.
Journal
|
DDX53 (DEAD-Box Helicase 53)
2ms
Machine learning of multiparametric MRI radiomics preoperatively distinguishes testicular seminoma from non-seminoma: a multicenter study. (PubMed, Abdom Radiol (NY))
A combined model utilising DWI, ADC, T2WI, and contrast-enhanced T1WI imaging, alongside AFP and cystic necrosis, demonstrates high precision, adaptability, and robustness in distinguishing seminoma from non-seminoma testicular tumors.
Clinical • Journal
|
AFP (Alpha-fetoprotein)
2ms
SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026
Trial primary completion date
|
CD4 (CD4 Molecule)
|
PD-L1 overexpression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
2ms
Clinical Manifestations, Tumor Associations, and Long-Term Outcomes of Anti-KLHL11 Encephalitis. (PubMed, Neurol Neuroimmunol Neuroinflamm)
Anti-KLHL11 encephalitis mainly related to infratentorial encephalitis but can also present as limbic encephalitis and rarely as meningitis. Early diagnosis enables early oncological and immunologic treatment, hopefully improving outcomes.
Retrospective data • Journal • IO biomarker
|
GFAP (Glial Fibrillary Acidic Protein)
2ms
Multi-omic screening identifies RBMXL3 as a primate-specific RNA-binding protein and candidate regulator of RNA metabolism in human spermatogenesis. (PubMed, Cell Mol Biol Lett)
Our findings for the first time identify primate-specific RBMXL3 protein as a new upstream regulator of RNA metabolism, characterized by broad RNA-binding activity in human TCam-2 cells. Finally, we show that RBMXL3 expression heavily reduces LINE-1 retrotransposition in human cells, underlying RBMXL3 importance in maintaining genome integrity. Our data suggest that RBMXL3 may contribute to the regulation of transcriptome dynamics in male germ cells, while its broader functional implications remain to be determined.
Journal
|
RBMX (RNA Binding Motif Protein X-Linked)